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Abstract
The persistence of human immunodeficiency virus type 1 (HIV-1) infection may be in part 
attributed to its ability to evolve to evade neutralizing antibody (NAb) surveillance. We have 
tested the prediction that positive selection of V3 is positively correlated with the strength of a
patient’s NAb response by analyzing a data set containing both sequences from the principal 
neutralizing domain of HIV-1 (V3) and measures of the strength of the NAb responses of several
patients. Only viral sequences from the patient with the strongest NAb response exhibited 
evidence of significant positive selection. To investigate the nature of selection by NAbs, we 
simulated the evolution of V3 at the nucleotide level. Two forms of plausible NAb selection were 
used: negative frequency-dependent selection and negative viral-age-dependent selection. 
Assuming negative age-dependent selection rather than negative frequency-dependent selection 
better simulated the temporal pattern of V3 variation from the patient with the strongest NAb 
response.
Introduction
The persistence of human immunodeficiency virus type 1 (HIV-1) infection may be attributed to
the virus’s ability to evade immune surveillance (Desrosiers 1999). Viral infection persists, even 
in the face of an initially vigorous cytotoxic T cell (CTL) response, apparently because HIV-1 is 
able to adapt to CTL surveillance through the evolution of CTL-escape variants (e.g., McMichael 
and Phillips 1997; da Silva and Hughes 1999; Evans, O'Connor et al. 1999). It is not clear, 
however, why even a strong neutralizing antibody (NAb) response is unable to clear the virus. 
One of the main targets of NAbs is the viral exterior envelope glycoprotein, gp120, which is 
situated on the virion surface and binds to host-cell chemokine coreceptor molecules during cell
entry (Profy, Salinas et al. 1990). Although high levels of antibodies are made against gp120,
most are not neutralizing or only weakly neutralizing (Desrosiers 1999). The inability of
antibodies to easily neutralize virions may be explained in part by the structure of the core of the
oligomeric form of gp120 on intact virions (Fouts, Binley et al. 1997; Kwong, Wyatt et al. 1998).
The 32-amino acid third variable loop (V3) of gp120 has been the focus of much research 
because of its importance as a NAb target (e.g., Spenlehauer, Saragosti et al. 1998; Nyambi,
Mbah et al. 2000), as a determinant of host-cell tropism (e.g., Speck, Wehrly et al. 1997), and
because variation within this region may be related to the rate of disease progression (Viscidi 
1999; Wolinsky and Learn 1999). Yet, neither the cause of variation nor the relationship between
variation and disease progression has been well established. Because V3 is involved in 
determining chemokine coreceptor usage by the virus, which determines cell tropism (e.g., Speck, 
Wehrly et al. 1997), it has been hypothesized that adaptation by the virus to a variety of cell types
causes diversification of V3 (Weiss 1996; Speck, Wehrly et al. 1997). A competing hypothesis
states that continuous selection of escape mutants by NAbs increases variation in V3 (Bonhoeffer, 
Holmes et al. 1995; Halapi, Leitner et al. 1997; Liu, Schacker et al. 1997). These hypotheses have 
been difficult to test because selection of V3 for neutralization resistance may change coreceptor
usage (McKnight, Weiss et al. 1995).
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V3 is a known target of monoclonal NAbs (Spenlehauer, Saragosti et al. 1998; Nyambi,
Mbah et al. 2000), and several NAb selection studies in vitro (McKnight, Weiss et al. 1995; 
Schonning, Jansson et al. 1996; Yoshida, Nakamura et al. 1997; Inouye, Cherry et al. 1998) and
in vivo using animal models (Cheng-Mayer, Brown et al. 1999; Etemad-Moghadam, Sun et al. 
1999) have reported amino acid replacements in V3 that affect neutralization. However, it 
remains to be demonstrated that HIV-1 V3 variation in humans is the result of in vivo selection by
NAbs.
Systems subject to apparently random perturbations, such as the error-prone reverse 
transcription of RNA and replication of DNA, can be modeled using Monte Carlo techniques, in
which a pseudorandom number generator is used to simulate random events (Haefner 1996). This
approach has been used to examine potential immune selection of HIV-1 at the molecular genetic 
level (Wiener 1996), showing that such selection can be detected by analyzing sequence data for 
evidence of positive selection. However, only one form of positive selection, frequency-
dependent selection, was modeled. In this type of selection, the fitness of an antigenic variant is 
inversely related to its relative frequency, as would be expected if immune surveillance were 
directed predominantly at the most common variants. However, antibody selection likely involves 
a time lag between the emergence of resistant variants and a neutralizing response to these 
variants, as has been shown for chimpanzees naturally infected with simian immunodeficiency
virus (SIVcpz) (Nyambi, Lewi et al. 1997) and humans infected with HIV-1 (Albert, 
Abrahamsson et al. 1990; Bradney, Scheer et al. 1999). Furthermore, because of computer
resource limitations, unrealistic viral population sizes and mutation rates were used in 
simulations. Our aim was to use Monte Carlo techniques and realistic parameter values to 
simulate antibody selection of V3 and compare the resulting temporal patterns of V3 variation to
the patterns determined empirically. This will help determine whether antibody selection is a 
plausible explanation of V3 variation, and, if so, what form of selection is likely operating. The 
form of selection will reflect the mode and tempo of antibody surveillance, knowledge of which 
should help to predict the evolutionary responses of HIV-1 to antibody vaccines. 
Methods
Nucleotide Substitution Distances 
Variation in V3 was measured by estimating mean synonymous and nonsynonymous nucleotide 
substitution distances between pairs of sequences. The mean number of synonymous substitutions
per potentially synonymous site (dS) and the mean number of nonsynonymous substitutions per 
potentially nonsynonymous site (dN) between all possible pairs of sequences and their variances 
are estimated using well-established algorithms (Nei and Gojobori 1986; Nei and Jin 1989). dS
and dN were corrected for multiple (and therefore unobserved) nucleotide changes at a single site 
by assuming that any nucleotide changes to any other nucleotide with equal probability across all 
sites (Jukes and Cantor 1969). In the absence of selection for amino acid replacement dN is 
expected to equal dS. However, with positive selection, dN is expected to exceed dS. The statistical 






where V(dS) and V(dN) are the variances of dS and dN, respectively. This value is compared to 
critical values from the t-distribution at 5, 1 and 0.1% significance and with infinite degrees of 
freedom (Kumar, Tamura et al. 1993). 
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Analysis of Empirical Data 
In a preliminary test of the hypothesis that HIV-1 V3 is under selection by NAbs, we tested the 
prediction that V3 variation is correlated with the strength of a patient’s NAb response and that
this variation results from positive selection. The dataset, consisting of sequences from the V3 
region sampled from six patients, is the result of a longitudinal study of the relationship between
CTL selection and disease progression (Wolinsky, Korber et al. 1996). However, the patients 
were also characterized for their NAb responses. This was measured as the geometric mean titer 
of the reciprocal dilution of late sera needed to neutralize 90% of the patient’s own (autologous)
virus.
Simulation of V3 Evolution 
The population of HIV-1 virus particles (virions) within a patient is represented as a data vector
in which each element contains the 96-nucleotide V3 sequence of one provirus (viral DNA 
integrated into host genome) (Fig. 1). A random number generator is used to mutate each 
nucleotide at an empirically estimated rate for HIV-1. Following mutation, nucleotide sequences 
are translated to amino acid sequences. Randomly chosen sequences (proviruses) are replicated 
with a probability proportional to their fitness, with fitness being determined by the form of 
selection. A constant population size is maintained by sampling (replicating) sequences with 
replacement until the desired next generation’s population size is reached, thus completing one 







Figure 1. A V3 nucleotide sequence data vector representing a 
simulated viral population of 106 virions within a patient.
1. initialize population nucleotide sequences
2. mutate nucleotide sequences
3. translate to amino acids
4. calculate fitness
5. replicate nucleotide sequences
Figure 2. Flow of the simulation program.
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Selection
The form of selection imposed by NAbs is not well understood. Therefore, two plausible forms of 
selection were explored. 
With negative frequency-dependent selection, the fitness of a viral variant is inversely
proportional to its relative frequency. This type of selection may arise if the NAb response is 
directed mainly at the most common viral variants. Frequency-dependent selection was 
implemented by simply counting the numbers of each V3 variant and then assigning fitness based 
on each variant’s relative frequency. This form of selection is described by W = 1 – fb, where W is 
the relative fitness (ranging from 0 to 1) of an amino-acid variant, f is the variant’s relative 
frequency, and b shapes the fitness function (and is constrained to be > 0) (Fig. 3A).
With negative age-dependent selection, the fitness of a viral variant declines 
exponentially with time (i.e. the number of viral generations) from the maximal value. This type
of selection may arise if there is a time lag in the NAb response. The temporal dynamics of 
antibody responses are not well understood, but a time lag in the response has been shown for 
chimpanzees naturally infected with SIVcpz (Nyambi, Lewi et al. 1997) (Hahn, Shaw et al. 2000) 
and humans infected with HIV-1 (Albert, Abrahamsson et al. 1990; Bradney, Scheer et al. 1999). 
Age-dependent selection was implemented by maintaining a database containing each variant 
sequence and its age in the current population. This database was then referenced in the next 
generation to determine the ages of the then current variants. Fitnesses were assigned on the bases 
of variants’ ages. Once a variant became extinct it was no longer maintained in the database, and
if it reappeared in the population (as a result of mutation from another existing variant) it was 
assigned an age of zero just like any other new variant. Age-dependent selection was described
with W = e-rt, where t is a variant’s age in generations and r is the rate of exponential decline in 
fitness. As r increases, fitness declines more precipitously with age (Fig. 3B). Estimates for r are 
not available, but, based on preliminary studies, values from 0.001 to 0.01 were used. 
Both forms of selection were expected to maintain genetic variation within a time point 
(diversity) because a variant’s fitness declines as it becomes either common or long-lived. 
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Figure 3. Forms of potential NAb selection. (A) Negative frequency-
dependent selection, in which the fitness of a variant is inversely
proportional to its relative frequency. (B) Negative age-dependent
selection, in which the fitness of a variant declines exponentially with its 
age (generations).
Population and Replication Parameter Values
Although the turnover rate of virions within a patient is on the order of 108 (Wei, Ghosh et al. 
1995) to 1010 (Perelson, Neumann et al. 1996) per day, the effective population size, that is, the 
number of virions that replicate, is much smaller: on the order of 105 (Rouzine and Coffin 1999).
A stable population of 105 virions was used in simulations, and populations of 104 and 106 were 
used to test the sensitivity of the results to changes in population size. The overall mutation rate, 
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including insertions and deletions of nucleotides, is estimated at 3.4 x 10-5 per nucleotide per 
replication cycle, whereas the mutation rate for nucleotide substitutions exclusively is 2.41 x 10-5
(Mansky and Temin 1995). A mutation rate of 10-5 was used in simulations, and mutation rates of 
10-6 and 10-4 were used to test the model’s sensitivity to the mutation rate. Mutation appears to be
biased in HIV-1, with a preponderance of G-to-A mutations. Relative rates of mutation between 
nucleotides (Wiener 1996) were used to determine the specific mutations that occur. That is, 
given that a nucleotide site is to be mutated, the specific mutation will depend on the nucleotide
present and the probability of that nucleotide mutating to each of the other three nucleotides. The
length of the replication cycle (generation time) of HIV-1 has been estimated, using mathematical
models, to be approximately 1.2 (Coffin 1995) to 2.6 (Perelson, Neumann et al. 1996) days per
cycle. A more recent investigation, using coalescent theory, has estimated this value to be 1.2 
(Rodrigo, Shpaer et al. 1999). Therefore, 1.2 days per cycle will be used in simulations. 
Simulation Runs 
Each run of a simulation consisted of 20 replicates of 1500 generations (60 simulated months)
each. Because of the stochastic nature of Monte Carlo simulation, replication is necessary to 
estimate the stochastic error of estimates of means. A sample size of 20 replicates is generally
considered the minimum required. 
For each simulation replicate 20 nucleotide sequences were chosen randomly from the 
population every 150 generations (equivalent to six months) and written to an external file. The 
output from each replicate is meant to mimic the output from an intensive empirical study.
Parallel Processing 
The simulation program, written in Fortran 90, was compiled using the IBM XL Fortran V. 6.1 
compiler. Because of the naturally parallel structure of Monte Carlo simulations, simulation runs 
consisted of 20 replicate simulations processed in parallel. The single program multiple data
programming model was implemented using the Message Passing Interface library of routines 
(Gropp, Lusk et al. 1994). Because of parallel processing, the pseudorandom number generator
has to produce an independent stream of pseudorandom numbers for each process and each 
stream has to have a period (the number of pseudorandom numbers generated before the sequence 
of numbers is repeated) that is greater than the number of pseudorandom numbers required by the
process. The Scalable Pseudorandom Number Generator (SPRNG) libraries 
(http://www.ncsa.uiuc.edu/Apps/CMP/RNG/RNG-home.html) were used to apply a Modified 
Lagged Fibonacci Generator with a period of approximately 21310 and 239617 distinct streams,
which were sufficient for the number of generations and replicates simulated. A random number
stream was generated for each simulation replicate, rather than each processor, to allow the exact 
same simulation to be reproduced (same seed value) regardless of the number of processors used.
This was useful in debugging the program.
Simulations were run on an IBM RS/6000 SP. One simulation run consisting of 20
replicate simulations required approximately 360 total CPU hours for a population size of 106
virions, 36 hours for 105 virions, and 3.6 hours for 104 virions. A maximum of 180 MB of run-
time memory were required to store information in various population vectors used during the 
most memory-intensive simulations (age-dependent selection) of the largest population size (106
virions).
Results and Discussion 
Empirical Patterns 
dN reflects amino acid diversity and can also be used to detect selection for amino acid 
replacement (positive selection). In these terms, the prediction is that dN will be higher in patients
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with a strong antibody response than in patients with a weak response and that only in strong
responders will dN exceed dS. The divergence of V3 in each patient was measured by estimating
dS and dN, as described above, from all possible pairwise comparisons between sequences from
one time point sample of sequences and the initial sample. dN exceeded dS significantly only for 
patient P4, the patient with the strongest NAb response (Fig. 4). The diversity of V3 in each 
patient was measured by estimating dS and dN from pairwise comparisons among sequences 
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Figure 4. Divergence dS and dN (± 1 SE) plotted against the number of
months post infection. NAb responses (see text) are given in parentheses
after the patient’s identification. Arrows mark the start of antiviral
therapy (zidovudine). Numbers of sequences sampled in each time-point
in chronological order: P1 (11, 8, 8, 8, 7); P2 (5, 6, 7, 4, 5, 7, 5, 2); P3
(8, 6, 6, 5, 5); P4 (11, 7, 7, 7, 8, 6); P5 (8, 9, 10, 7, 11, 11, 6); P6 (10, 6,
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Figure 5. Diversity dS and dN (± 1 SE) plotted against the number of 
months post infection. Symbols and sample sizes are as in Figure 2.
Tests of dS = dN: *P < 0.05; ***P < 0.001.
Model Test 
We tested the routines fundamental to the model, that is, those implementing mutation and 
replication (and hence pseudorandom number generation), in the absence of selection by









where xi is the frequency of the i
th of q alleles (amino-acid variants). The average gene diversity 
expected under strict neutrality (no selection) and at equilibrium for an infinite-alleles model








(Nei 1987, p. 377), where N is the haploid effective population size (stable number of virions) 
and v is the per-sequence mutation rate. The per-sequence mutation rate is calculated as v = µ x 
nN, where µ is the per nucleotide mutation rate and nN is the number of nonsynonymous (amino
acid changing) nucleotide sites in the simulated sequence. Simulations were run without selection 
for 5,000 generations or until equilibrium was reached (h remained constant). The variance of h
was estimated for each time point from 20 replicate simulations. The equilibrium value of h was 
compared to the expected value. Tests were conducted with parameter values N = 104, 105, and µ
= 10-4, 10-5. In all cases, observed average gene diversities at equilibrium matched expected gene 
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Figure 6. Average gene diversity (h) (± 1 SE) plotted against viral
generation for two effective population sizes (N) and two per-sequence
mutation rates (v) from 20 replicate simulations. Dotted reference lines
show the expected gene diversity (E(h)) under strict neutrality at 
equilibrium for the infinite-alleles model.
Simulated Patterns 
With frequency-dependent selection, diversity dN rose quickly and then remained relatively
constant and higher than dS (Fig. 7A). With age-dependent selection, there was a lag in the 
increase in dN, but then a long period of increase (Fig. 7B). The latter result more closely mimics
the empirical result from the patient with a strong NAb response (P4) (Fig. 5). These results 























































Figure 7. Results from one replicate simulation of NAb selection.
Diversity dS (dashed line) and dN (solid line) for 20 simulated V3 
sequences sampled at various times post-infection (PI). Z-tests: *P < 
0.05; **P < 0.01; ***P <0 .001. (A) Negative frequency-dependent
selection with a linear fitness function. (B) Negative age-dependent
selection with r = 0.001.
Conclusion
These results support the hypothesis that HIV-1 evolves in response to selection by NAbs. The 
empirical data show evidence of positive selection of V3 only in the patient with the strongest 
NAb response. The pattern of change in diversity dN in this patient is better simulated with 
negative age-dependent selection than with negative frequency-dependent selection. This implies
that there is a time lag in the production of antibodies to newly emerged V3 variants. This 
conclusion is consistent with results from studies of the tempo of antibody selection of SIVcpz 
infecting chimpanzees (Nyambi, Lewi et al. 1997) and HIV-1 infecting humans (Albert, 
Abrahamsson et al. 1990; Bradney, Scheer et al. 1999).
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